Patents Represented by Attorney, Agent or Law Firm Janet E. Hasak
  • Antibody to osteoclast alphavbeta3 ntegrin
    Patent number: 5578704
    Abstract: Hybridoma cell line, ATCC HB 11029, which produces murine monoclonal antibody, 10C4.1.3 which specifically binds to alphavbeta3 integrin on human osteoclasts, and is capable of blocking binding of alphavbeta3 integrin to fibrinogen or to vitronectin. The antibody is useful for detecting alphavbeta3 integrin on cells in histological and diagnostic assays, and to treat disease conditions that are characterized by excessive bone resorption.
    Type: Grant
    Filed: September 30, 1994
    Date of Patent: November 26, 1996
    Assignee: Genentech, Inc.
    Inventors: Kyung J. Kim, Michael A. Horton, Sarah C. Bodary, Anan Chuntharapai
  • Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy
    Patent number: 5573762
    Abstract: A leukemia inhibitory factor antagonist, alone or in combination with an endothelin antagonist, may be used for treatment of heart failure. The antagonist(s) are administered in a chronic fashion, in therapeutically effective amounts, to achieve this purpose.
    Type: Grant
    Filed: April 24, 1995
    Date of Patent: November 12, 1996
    Assignee: Genentech, Inc.
    Inventors: Napoleone Ferrara, Kathleen King, Elizabeth Luis, Jennie P. Mather, Nicholas F. Paoni
  • Cardiac hypertrophy factor
    Patent number: 5571893
    Abstract: Isolated CHF, isolated DNA encoding CHF, and recombinant or synthetic methods of preparing CHF are disclosed, These CHF molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.
    Type: Grant
    Filed: August 5, 1994
    Date of Patent: November 5, 1996
    Assignees: Genentech, Inc., Regents of the Univ. of California
    Inventors: Joffre Baker, Kenneth Chien, Kathleen King, Diane Pennica, William Wood
  • Detection and amplification of candiotrophin-1(cardiac hypertrophy factor)
    Patent number: 5571675
    Abstract: Isolated CHF, isolated DNA encoding CHF, and recombinant or synthetic methods of preparing CHF are disclosed. These CHF molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: November 5, 1996
    Assignees: Genentech, Inc., Regents of the Univ. of California
    Inventors: Joffre Baker, Kenneth Chien, Kathleen King, Diane Pennica, William Wood
  • Method of administration of IGF-I
    Patent number: 5565428
    Abstract: A method is disclosed that comprises administering insulin-like growth factor-I (IGF-I) to a mammal so as to sustain its biological activity in the mammal comprising administering a therapeutically effective amount of IGF-I to the mammal to provide an exposure to IGF-I for a period of time that stimulates the maximum biological response in the mammal, then discontinuing said administration for a period of time equal to or less than the time period used for administration, and repeating this pattern of administration and discontinuance of administration for a period as long as necessary to achieve or maintain the desired biological response in the mammal.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: October 15, 1996
    Assignees: Genentech, Inc., Washington University
    Inventors: Ross G. Clark, Neil Gesundheit, Marc R. Hammerman, Steven B. Miller
  • Use of human inhibin and human activin to increase the number of mature primate oocytes
    Patent number: 5563059
    Abstract: A method is provided for increasing the fertilization potential of oocytes comprising culturing oocytes in vitro with an effective amount of inhibin, activin, or a combination of inhibin and activin. Preferably the oocytes being cultured are immature. After the culturing step, the oocytes can be fertilized. The oocytes are suitably cryopreserved and thawed before the culturing step.
    Type: Grant
    Filed: February 23, 1993
    Date of Patent: October 8, 1996
    Assignees: Genentech, Inc., Medical Research Foundation of Oregon
    Inventors: Baha M. Alak, Richard L. Stouffer, Don P. Wolf, Teresa K. Woodruff
  • Methods for the detection of acid-labile subunit (ALS) of insulin-like growth factor binding protein complex
    Patent number: 5561046
    Abstract: An acid-labile protein is described that, when incubated with the 53-Kd acid-stable protein occupied by IGF, converts it to a high molecular weight complex, corresponding to the in vivo form of IGF. This protein is called the acid-labile subunit (ALS) of IGF binding protein complex and is provided in biologically pure form. ALS is useful in treating wounds and promoting cellular growth. The nucleic acid encoding ALS, antibodies binding thereto, and fragments thereof are also disclosed.
    Type: Grant
    Filed: March 14, 1994
    Date of Patent: October 1, 1996
    Assignee: Genentech, Inc.
    Inventor: Robert C. Baxter
  • Method for predicting and/or preventing preterm labor
    Patent number: 5545616
    Abstract: A method is provided for avoiding premature labor in a pregnant mammal comprising administering to said mammal, during labor, but before an infant is to be delivered, an effective amount of an activin antagonist. In one embodiment, the antagonist is follistatin. In another aspect a method is provided for assaying whether a pregnant mammal is in imminent delivery of its fetus in preterm labor comprising contacting a maternal serum sample or amniotic fluid sample of the mammal with a reagent that detects activin A and measuring the level of activin A in the serum or amniotic fluid. In addition, a kit for the assay is provided.
    Type: Grant
    Filed: September 22, 1994
    Date of Patent: August 13, 1996
    Assignee: Genentech, Inc.
    Inventor: Teresa K. Woodruff
  • Cardiac hypertrophy factor and uses therefor
    Patent number: 5534615
    Abstract: Isolated CHF, isolated DNA encoding CHF, and recombinant or synthetic methods of preparing CHF are disclosed. These CHF molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.
    Type: Grant
    Filed: April 25, 1994
    Date of Patent: July 9, 1996
    Assignees: Genentech, Inc., The Regents of the University of California
    Inventors: Joffre Baker, Kenneth Chien, Kathleen King, Diane Pennice, William Wood
  • Nucleic acid encoding the mature .alpha. chain of inhibin and method for synthesizing polypeptides using such nucleic acid
    Patent number: 5525488
    Abstract: DNA encoding the prepro inhibin .alpha. and .beta. chains has been isolated. This DNA is ligated into expression vectors and used to transform host cells for the preparation of inhibin or activin. Also provided are prohormone domains and other inhibin .alpha. or .beta. chain derivatives having therapeutic or diagnostic interest. The compositions provided herein are useful in the manipulation of fertility in animals.
    Type: Grant
    Filed: February 17, 1994
    Date of Patent: June 11, 1996
    Assignee: Genentech, Inc.
    Inventors: Anthony J. Mason, Peter H. Seeburg
  • Tangential flow filtration process and apparatus
    Patent number: 5490937
    Abstract: Processes and apparati are provided for separating species of interest from a mixture containing them which comprises subjecting the mixture to tangential-flow filtration, wherein the filtration membrane preferably has a pore size that retains species with a size up to about 10 microns, and the flux is maintained at a level ranging from about 5 % up to 100 % of transition point flux.
    Type: Grant
    Filed: July 6, 1994
    Date of Patent: February 13, 1996
    Assignee: Genentech, Inc.
    Inventor: Robert D. van Reis
  • Method of determining propensity of dissolved oxygen instability
    Patent number: 5487980
    Abstract: A process for producing a polypeptide of interest from fermentation of bacterial host cells comprising nucleic acid encoding the polypeptide is provided. In this method, the host cells employed have an inactivated electron transport chain. Further provided is a method for determining if a particular bacterial cell culture has a propensity for dissolved oxygen instability when fermented on a large scale.
    Type: Grant
    Filed: May 9, 1994
    Date of Patent: January 30, 1996
    Assignee: Genentech, Inc.
    Inventor: James R. Swartz
  • Nucleic acid encoding TGF-.beta. and its uses
    Patent number: 5482851
    Abstract: Nucleic acid encoding TGF-.beta. has been isolated and cloned into vectors which are replicated in bacteria and expressed in eukaryotic cells. TGF.beta. is recovered from transformed cultures for use in known therapeutic modalities. Nucleic acid encoding TFG-.beta. is useful in diagnosis and identification of TGF-.beta. clones.
    Type: Grant
    Filed: November 5, 1993
    Date of Patent: January 9, 1996
    Assignee: Genentech, Inc.
    Inventors: Rik M. A. Derynck, David V. Goeddel
  • Antibodies to human carboxypeptidase B and methods of use thereof
    Patent number: 5474901
    Abstract: A novel polypeptide, designated plasma carboxypeptidase B (PCPB), has been purified from human plasma. It has been cloned from a human liver cDNA library using PCR amplification. Provided herein is nucleic acid encoding PCPB useful in diagnostics and in the recombinant preparation of PCPB. PCPB is used in the preparation and purification of antibodies thereto, in the purification of plasminogen, in the inhibition of plasminogen activation by t-PA in the presence of fibrinogen, and in diagnostic assays.
    Type: Grant
    Filed: July 19, 1994
    Date of Patent: December 12, 1995
    Assignee: Genentech, Inc.
    Inventors: Dennis T. Drayna, Dan L. Eaton
  • Method for purifying polypeptides
    Patent number: 5451660
    Abstract: A process is provided for selectively separating a polypeptide of interest from components of differing hydrophobicity in a mixture comprising the steps of:(a) passing the mixture through underivatized silica particles such that the polypeptide adheres to the silica particles;(b) washing the silica particles to remove impurities; and(c) eluting the polypeptide from the silica particles with a buffer comprising an alcoholic or polar aprotic solvent and an alkaline earth, an alkali metal, or an inorganic ammonium salt.
    Type: Grant
    Filed: December 13, 1993
    Date of Patent: September 19, 1995
    Assignee: Genentech, Inc.
    Inventors: Stuart E. Builder, Charles V. Olson, David Reifsnyder
  • Purification of insulin-like growth factor
    Patent number: 5446024
    Abstract: A process for purifying IGF-I from variants of IGF-I is provided. In this process a mixture containing IGF-I and its variants is loaded onto a reversed-phase liquid chromatography column and the IGF-I is eluted from the column with a buffer at a pH of about 6-8. The buffer contains an alcoholic or polar aprotic solvent at a concentration of about 20-30% (v/v). This process can be preceded by a hydrophobic-interaction chromatography step.
    Type: Grant
    Filed: December 17, 1993
    Date of Patent: August 29, 1995
    Assignee: Genentech, Inc.
    Inventors: Stuart E. Builder, John R. Ogez, Charles V. Olson, David Reifsnyder
  • TGF-.beta. composition for inducing bone growth
    Patent number: 5409896
    Abstract: A method is provided for generation of bone at a site of an animal where skeletal tissue is deficient comprising administering to the animal, locally at the bone site in the presence of a source of osteogenic cells, an effective amount of a composition comprising TGF-.beta. in a pharmaceutically acceptable carrier, provided that such composition excludes a bone morphogenetic cofactor, the composition being administered in an amount effective to induce bone growth at the bone site. Also provided is a device for implantation into a site of an animal where skeletal tissue is deficient comprising a device treated with an effective amount of a composition comprising TGF-.beta. and a source of osteogenic cells in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: November 12, 1993
    Date of Patent: April 25, 1995
    Assignee: Genentech, Inc.
    Inventors: Arthur J. Ammann, Christopher G. Rudman
  • Method for refolding insoluble, misfolded insulin-like growth factor-1 into an active conformation
    Patent number: 5410026
    Abstract: A method for refolding insoluble, improperly folded IGF-I is provided, wherein the IGF-I, precipitated from prokaryotic host cells, is concurrently solubilized, unfolded, and refolded into a biologically active conformation in a single buffer. The buffer contains reducing agent and chaotropic agent to solubilize the IGF-I at concentrations sufficiently low to allow solubilization and refolding to occur. Also provided is a triple-protease deficient E. coli host suitable for use in the process.
    Type: Grant
    Filed: December 2, 1993
    Date of Patent: April 25, 1995
    Assignee: Genentech, Inc.
    Inventors: Judy Y. Chang, Nancy C. McFarland, James R. Swartz
  • Aqueous multiple-phase isolation of polypeptide
    Patent number: 5407810
    Abstract: A method is described for isolating an exogenous polypeptide in a non-native conformation from cells, such as an aqueous fermentation broth, in which it is prepared comprising contacting the polypeptide with a chaotropic agent and preferably a reducing agent and with phase-forming species to form multiple aqueous phases, with one of the phases being enriched in the polypeptide and depleted in the biomass solids and nucleic acids originating from the cells. Preferably, the method results in two aqueous phases, with the upper phase being enriched in the polypeptide.
    Type: Grant
    Filed: August 20, 1993
    Date of Patent: April 18, 1995
    Assignee: Genentech, Inc.
    Inventors: Stuart Builder, Roger Hart, Philip Lester, John Ogez, David Reifsnyder
  • Growth-promoting composition and its use
    Patent number: 5374620
    Abstract: A combined formulation for IGF-I and growth hormone (GH) is useful for enhancing growth of a mammal. This formulation, which may be administered by infusion or injection to enhance growth, comprises IGF-I and GH, each in amounts of 0.1 to 100 mg/ml, in a pharmaceutically acceptable carrier at a pH of about 5-6 containing a surfactant, wherein the amounts of IGF-I and GH in the composition are effective to promote growth of a mammal more than an equivalent dose of IGF-I or GH alone, and wherein the weight ratio of IGF-I to GH in the composition ranges from 0.002:1 to 240:1.
    Type: Grant
    Filed: June 4, 1993
    Date of Patent: December 20, 1994
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Michael J. Cronin, Douglas A. Yeung, James Q. Oeswein